Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
DUBLIN, Ireland, May 25, 2021 – Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis will participate in a fireside chat on June 1 at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DUBLIN, Ireland, May 25, 2021 – Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis will participate in a fireside chat on June 1 at 9:00 a.m. ET. This event will focus on FT218, an investigational once-nightly formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. A live webcast and an archived recording will be accessible on Avadel’s Investor Relations website for 90 days following the conference.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was -1.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Tuesday, June 1 at 9:00 a.m. ET.
A live webcast of this event, as well as an archived recording, will be available on Avadel’s Investor Relations website, www.investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.